Given that cone and rod recovery, as well as the
RCB, had the best diagnostic capacity, we applied these parameters to consider whether high-risk clinical profiles
28 29 varied in their average ± SD recovery parameters in our ARM group
(Table 1) . Study eyes with drusen and no pigment change (
D + P −;
n = 9) were no different from those that had both drusen and pigment change (
D + P +;
n = 18;
R c D + P − 0.93 ± 0.21 vs.
R c D + P + 1.02 ± 0.40 decades · min
−1,
P > 0.05;
R r D + P − 0.15 ± 0.06 vs.
R r D + P + 0.14 ± 0.06 decades · min
−1,
P > 0.05;
RCB D + P − 18.37 ± 4.79 minutes versus
RCB D + P + 19.49 ± 5.46 minutes,
P > 0.05). Study eyes with an AMD fellow eye (
n = 5,
Table 1 ), showed a nonsignificant trend for slower recovery compared with cases with bilateral ARM (
R c AMD in the fellow eye,
n = 5, 0.98 ± 0.36 vs.
R c ARM in the fellow eye,
n = 22, 1.05 ± 0.34 decades · min
−1,
P > 0.05;
R r AMD in the fellow eye,
n = 5, 0.18 ± 0.03 vs.
R r ARM in the fellow eye,
n = 22, 0.16 ± 0.03 decades · min
−1,
P > 0.05). The cases with unilateral AMD also showed a nonsignificant trend for slower
RCB. Two cases (one geographic atrophy, one choroidal neovascularization [CNV]) did not show an
RCB within the 30 minutes of testing
(Fig. 5D)and the remaining three CNV cases had an average
RCB of 22.86 ± 2.69 minutes compared with the 18.58 ± 5.26 minutes found in cases with bilateral ARM (
n = 22,
P > 0.05). Nevertheless, although there were trends for slower recovery in these clinical subgroups, the average trend was not statistically significant. This result is presumably due to the small sample size of our ARM cohort, and further investigation with larger sample sizes is warranted.